The questions readers ask most often, with sourced answers. If you have a question we haven’t covered, the full investigation is at /investigations and /evidence.
No. Independent lab testing of gray-market semaglutide consistently finds catastrophic purity failures (as low as 7.7% actual content vs. 99% labeled), endotoxin contamination in 100% of samples tested in peer-reviewed studies, mislabeled compounds (samples sold as semaglutide that tested as cagrilintide or even insulin glargine), and quantities that vary up to 45% from advertised. There is no FDA oversight, no medical screening, no licensed pharmacy in the supply chain, and the product may have spent weeks at room temperature in shipping. The 2024 JMIR study found semaglutide labeled “99% pure” contained as little as 7.7% actual semaglutide. See the purity data →
glp1forum.com is an unofficial community forum where users discuss compounded and gray-market GLP-1 medications, vendor reviews, dosing protocols, and Janoshik test results. It is not affiliated with any pharmaceutical manufacturer or regulator. The forum has documented multiple vendor failures over time — the Modern Peptides COA forgery, Coastal Peptides selling cagrilintide as semaglutide, ERP underfilled vials with high endotoxin. Anything you read there is anecdote, not medical advice. We cite specific threads as primary-source documentation of community-reported failures, but they remain unverified by us. Use the forum to read what the community is saying. Do not use it as a substitute for medical advice from a licensed provider.
No. Compounded semaglutide is not FDA-approved. Compounded medications are produced by 503A or 503B compounding pharmacies under federal pharmacy law, which is legal, but the FDA does not review or approve compounded formulations for safety or effectiveness. This is different from gray-market research peptides (which are illegal). LegitScript-certified compounded telehealth providers (Eden, bmiMD, Enhance MD, Get Thin MD, Breeze Meds, Sprout Health) prescribe via licensed US pharmacies with provider oversight — legal, but not FDA-approved. Brand Wegovy, Ozempic, and Zepbound are FDA-approved. See the full breakdown →
Janoshik issues every test report a unique sample ID. The only way to confirm a COA is genuine is to enter that ID at janoshik.com/verify and check what the database returns. If the analyte, batch, and purity match the certificate the vendor sent you, the test is real. If they don’t, you’re looking at a forgery. Fewer than one in ten buyers actually use this verification step. Modern Peptides was caught with a forged NAD+ COA where the actual Janoshik test on file was for QSC bacteriostatic water — caught only because a buyer ran the lookup. Even when a Janoshik COA is verified real, it tested one vial from one batch on one day. Yours is a different vial. Read the full COA fraud investigation →
As of 2026, Wegovy through NovoCare’s direct-to-consumer pharmacy is $349/month at the manufacturer’s flat price, dropping to $25/month with the Wegovy Savings Card for eligible commercially insured patients. Oral Wegovy is $149/month. Ro charges $199/month for brand Wegovy via the Novo partnership. LillyDirect Zepbound vials start at $299/month. The 2023 price gap that built the gray market — when brand was $1,000+/month — has collapsed. Compare full pricing →
Janoshik Analytical reported that 43% of peptides tested in 2024 failed to meet their label purity claims. ACS Peptide Labs (1,200+ samples, 2024-2026) found 73% of samples had purity discrepancies versus the supplier’s COA, with an average shortfall of 8.4 percentage points. 41% were off by more than 10 points. The Finnrick Analytics database (6,937 samples, 205 vendors) shows ±45% normal quantity variance from advertised vial amounts. A 2024 peer-reviewed study (PMC 11582493) found three illegal online pharmacies selling semaglutide labeled “99% pure” that tested at 7.7%, 8.97%, and 14.37% actual purity. See the data →
Retatrutide is not FDA-approved as of 2026. There is no legal source for retatrutide in the United States. Eli Lilly compound code LY3437943 is still in Phase 3 trials (the TRIUMPH program). No licensed pharmacy can compound it. No telehealth provider can prescribe it. No FDA-approved retatrutide product exists. Every retatrutide vial currently in circulation in the US came from a gray-market peptide vendor sourcing API from China, with every safety risk documented across this site. FDA approval is expected sometime in 2027 at earliest. Until then, the only legitimate path is to wait, or to discuss tirzepatide (FDA-approved Zepbound, or LegitScript-certified compounded tirz) with a licensed provider — tirzepatide is a dual GIP/GLP-1 agonist with similar weight-loss outcomes to retatrutide in published trials. See compounded tirz options →
Retatrutide is Eli Lilly’s investigational triple-agonist for obesity and type 2 diabetes — it activates three receptors at once: GLP-1, GIP, and glucagon. Semaglutide (Wegovy / Ozempic) is a single GLP-1 agonist. Tirzepatide (Zepbound / Mounjaro) is a dual GIP/GLP-1 agonist. Retatrutide adds the glucagon receptor, which in published Phase 2 data drove higher weight-loss numbers than either competitor — roughly 24% body-weight reduction at 48 weeks in the highest-dose arm. The clinical promise is what’s driving the gray-market demand. The clinical safety data is also less mature: there is significantly less long-term human safety data on retatrutide than on the approved drugs, and no FDA-issued boxed warning, dose schedule, or monitoring guidance for non-trial use. Compound code: LY3437943.
Gray-market retatrutide carries every risk that gray-market semaglutide and tirzepatide carry — purity failures, endotoxin contamination, mislabeled compounds, cold-chain degradation, customs seizure — plus additional risk because it is an investigational drug with limited human safety data outside of controlled trials. The Finnrick Analytics retatrutide dataset (2,557 samples, 166 vendors) shows purity discrepancies and ±45% quantity variance consistent with the rest of the gray market. The peptide community routinely reports vendor failures specific to retatrutide: Quenna PMQ tested as “sample does not contain Tirzepatide” on a labeled retatrutide product (April 2026); Coastal Peptides was caught selling cagrilintide as semaglutide using the same supply chain that handles their retatrutide. There is no legal recourse if a gray-market reta vial harms you, and no provider managing your dosing or side-effect monitoring. See the lab data →
Eli Lilly’s Phase 3 TRIUMPH program for retatrutide is ongoing. Phase 3 readouts and FDA submission are expected through late 2026 and into 2027. FDA approval timeline depends on trial outcomes, manufacturing readiness, and regulatory review — realistic earliest approval is 2027, possibly later. Until that point, retatrutide is only legally available through participation in a clinical trial. Anyone selling retatrutide outside of a trial is operating in the gray market, regardless of how the product is described or labeled. We are tracking enforcement actions against retatrutide vendors on our enforcement tracker.
Retatrutide has become the highest-volume peptide on glp1forum and the related subreddits because it is the only major GLP-1-class compound with no legal alternative. Semaglutide buyers can switch to brand Wegovy at $25-$349/mo or compounded telehealth. Tirzepatide buyers can switch to Zepbound vials or compounded tirz. Retatrutide buyers cannot switch — there is no FDA-approved or LegitScript-certified compounded path, anywhere. So gray-market vendors capture 100% of the demand, and the community generates a constant stream of vendor reviews, dose protocols, and Janoshik COAs trying to identify which vendor is least likely to harm them. Forums like glp1forum.com publish vendor warnings (Modern Peptides COA forgery, ERP underfilled vials, Quenna PMQ wrong-compound shipment) precisely because the failure rate on this product is high and the legal alternative does not yet exist.
Yes, and they regularly do. The 2024 NABP RogueRx Activity Report found that the FDA caught 44 of 239 unauthorized GLP-1 shipments tracked — an 18% interception rate. CBP Cincinnati intercepted 5,000+ peptide shipments from a single Chinese sender in late 2024, and seized 16,740 unapproved weight-loss medications worth $3.5M across 2025. Operation Pangea XVII (Interpol-led) made 769 arrests and seized 50.4 million doses of illicit pharmaceuticals worth $65 million across 90 countries in 2024-2025. Shipments are typically mismanifested as cosmetics, dog food, tea, or t-shirts. If your shipment is intercepted, you receive a notice; possession charges against individual buyers remain rare, but seizures are routine. See the full seizure data →
The “not for human consumption” or “for research only” label is a legal fig leaf vendors use to evade FDA enforcement under the “research chemicals” loophole. The FDA’s official position, restated in 2024 guidance, is that this disclaimer is legally ineffective when marketing context, customer base, and product format all signal human use. Vendors selling injectable peptides marketed to weight-loss communities while calling them “research chemicals” have been successfully prosecuted (Watkins indictment April 2026, Paradigm Peptides, BioPeptide Labs). The disclaimer protects the seller’s argument; it does not protect the buyer.
It depends on your priorities. For brand-name FDA-approved Wegovy or Zepbound: Ro ($199/mo, Novo Wegovy partner), LillyDirect ($299/mo manufacturer-direct Zepbound), NovoCare ($349/mo or $25/mo with savings card), LifeMD, Fella Health (men’s). For LegitScript-certified compounded GLP-1 with full medical oversight at lower cost: Eden Health ($149/mo intro), Enhance MD ($49/mo intro), bmiMD, Get Thin MD, Breeze Meds, Sprout Health. All listed providers have a US-licensed physician evaluating you, a licensed pharmacy filling the prescription, and ongoing monitoring. See the full Find Care directory →
Endotoxin (lipopolysaccharide / LPS) is bacterial cell-wall fragments released when Gram-negative bacteria die. Injecting endotoxin causes fever, septic shock, hypotension, and severe injection-site reactions. The 2024 JMIR study found endotoxin in 100% of gray-market semaglutide samples tested. SemaSpace tested at 8.95 EU/mg, well above pharmaceutical safety thresholds. Endotoxin contamination indicates the manufacturing environment was not sterile and bacterial cultures were present at some point during production. Legitimate pharmaceutical compounding requires LAL endotoxin testing on every batch — Janoshik and similar gray-market labs do not run this test.
Most people who stop taking semaglutide regain a significant portion of the weight they lost — published research shows about two-thirds of weight loss is regained within a year of stopping. Appetite returns to baseline as the medication clears. Cardiometabolic improvements (blood pressure, blood sugar, lipids) typically reverse alongside weight regain. This is why long-term treatment plans through licensed telehealth — with provider monitoring of side effects and dose adjustments — are designed for sustained use, not as a quick fix. Stopping abruptly without provider guidance can also cause GI rebound. Always taper under medical supervision.
Yes. The FDA Adverse Event Reporting System (FAERS) documented 17 deaths linked to GLP-1s obtained without licensed medical oversight as of December 2024. The Baltimore Sun reported 8,000+ Marylanders sickened by unregulated GLP-1 products in a single year. America’s Poison Centers reported a 1,500% increase in poison control calls related to GLP-1 use since 2019, driven heavily by gray-market peptides. FDA has logged over 1,000 adverse event reports for compounded semaglutide and tirzepatide as of mid-2024 — including pancreatitis, gallbladder disease, kidney injury, severe hypoglycemia, and acute liver failure. See the human cost →
Typical end-to-end transit is 10 to 45 days, none of it temperature-controlled. Manufacturing in China takes 3-30 days. Air freight to a US broker takes 7-15 days. Time sitting in a warehouse before final mailing is indeterminate. Standard postal delivery is final-mile. Compare this to legitimate pharmacy fulfillment: 2-3 days door-to-door with continuous cold-chain monitoring at 2-8°C. GLP-1 peptides are temperature-sensitive — a 2015 PLOS ONE study found peptide hormone recovery is impaired after just one hour at room temperature.
LegitScript-certified compounded telehealth (Eden, bmiMD, Enhance MD, etc.) involves a US-licensed physician evaluating you via medical intake, a 503A or 503B compounding pharmacy filling a real prescription, ongoing provider monitoring of your dose and side effects, LegitScript and HIPAA compliance, malpractice insurance, and a state medical board complaint process if something goes wrong. Gray-market peptide vendors (research-peptide sites, Telegram brokers, “not for human consumption” sellers) involve no provider, no prescription, no licensed pharmacy, no oversight, no recourse if you’re harmed, and Chinese-origin API of unverified purity. Both involve compounded molecules; the medical infrastructure around them is what makes one legal and one not. Read our full breakdown →
Dr. Justin Watkins is a Utah osteopathic physician indicted by the DOJ in April 2026 for distributing Chinese-origin unapproved peptides to over 200 patients. He purchased semaglutide, tirzepatide, retatrutide, cagrilintide, and NAD+ from a vendor called “Swole as F*** Research,” paid via Venmo with payments labeled “meal prep,” and received blank Chinese vials in boxes with Chinese/English lettering. He relabeled them with fake physician labels and injected them into patients without disclosing the source. He made $249,044 in nine months. The case demonstrates that the “research chemicals” label provides no legal protection when the products end up in human patients.
Lottie Moss, a 110-pound model, took semaglutide from a peptide vendor she found online. The dose she was given was calibrated for someone over 220 pounds — twice her body weight. There was no medical screening, no body-weight check, no dose adjustment by a clinician. She had a seizure. Her friend held her feet down until the convulsions stopped. She publicly described it as “the scariest thing that’s ever happened to me in my life.” Clinical pharmacologists confirmed the dosing discrepancy was twice the maximum safe dose for her body weight. The case is a clear illustration of what happens when GLP-1s are used without licensed medical oversight: no one is checking whether the dose is appropriate for the patient.
Hims has transitioned its weight-management offering to brand Wegovy via a Novo Nordisk partnership announced in 2026. Their previous compounded semaglutide program sourced from MedisourceRx, a LegitScript-certified compounding pharmacy that received an FDA Form 483 in March 2026 documenting a live spider in the compounding room and a dead cricket in the incubator room. A patient on their product was hospitalized for three nights. Even LegitScript-certified compounding pharmacies are not immune to inspection failures. Brand Hims Wegovy via the Novo partnership is FDA-approved formulation.
Federal enforcement against gray-market peptide vendors has accelerated in 2024-2026. Amino Asylum was raided in June 2025 with inventory seized. Paradigm Peptides founders pleaded guilty in December 2025 to introducing unapproved new drugs into interstate commerce. Peptide Sciences — the community’s “gold standard” with $7.4M/month in revenue — shut down overnight in March 2026 with a three-sentence goodbye. PeptideElite vanished with $5,000-$10,000 in unfulfilled customer orders. The pattern: when a vendor is raided or chooses to exit, customer money disappears, no recall mechanism exists, and any future harm has no recourse path. There is no FDIC for research peptides. See the full graveyard →
A real Janoshik COA includes: lab letterhead with the Janoshik Analytical name, a unique sample ID, a QR code or unique key for verification at janoshik.com/verify, the analyte tested, HPLC purity percentage with chromatogram, mass spectrometry identity confirmation, batch/lot number matching the vial, date of analysis, and an analyst signature. Forgery red flags include: identical batch numbers across different products, perfect round-number purity (exactly 99.00%) on every COA, scrubbed QR codes, missing analyst signature, dates that predate the product manufacture date, and “tested by Jano” claims that fail verification when the ID is checked at the lab portal.
503A compounding pharmacies prepare individualized compounded medications for specific patients with valid prescriptions; they’re licensed by state boards of pharmacy. 503B outsourcing facilities can produce compounded medications in larger quantities for hospitals and clinics; they register with the FDA and submit to FDA inspection. Both categories were formalized under the Drug Quality and Security Act of 2013 after the 2012 New England Compounding Center contamination outbreak. LegitScript-certified compounded telehealth providers source from these licensed facilities. Compounded medications from 503A/503B pharmacies are legal but not FDA-approved formulations — different from research-peptide vendors, who are not licensed pharmacies.
FDA-approved semaglutide is the base form (the molecule used in Wegovy and Ozempic). Some gray-market vendors sell semaglutide sodium or tirzepatide sodium — chemically different molecules that have never been tested in humans. Novo Nordisk and Eli Lilly have publicly flagged these salt forms as not therapeutically equivalent to the approved drugs, and the FDA has explicitly warned that compounding pharmacies using salt forms are operating outside the legal compounding framework. If a vendor or compounding pharmacy lists “semaglutide sodium” or “tirzepatide sodium” on the COA, it is not the same molecule patients see in Wegovy or Zepbound.
Personal-use possession prosecutions of individual buyers are rare in the US. Federal enforcement focuses on sellers, distributors, and clinicians who dispense unapproved drugs (Watkins, Paradigm Peptides founders, BioPeptide Labs). However, the legal risk is not zero: customs interception is routine, packages are seized, and the FDA can refer cases. The bigger practical risk is medical: there is no recall mechanism if you are harmed, no malpractice insurance, no liability claim, and no way to identify what was actually in your last vial. Read the legal risk analysis →
Stop using the product immediately. Contact a US-licensed healthcare provider — urgent care, emergency room, or your primary care doctor depending on severity. Bring the vial and any packaging. Symptoms that require immediate medical attention: severe abdominal pain (potential pancreatitis or gallbladder issue), persistent vomiting (potential gastroparesis or intestinal obstruction), jaundice or right-upper-quadrant pain (liver injury), severe hypoglycemia symptoms (counterfeits have contained insulin), high fever or septic symptoms (endotoxin reaction), severe injection-site infection. Report adverse events to the FDA at FAERS (faers.fda.gov). Do not assume the vial contained what the label said.
Use our three-layer test. (1) Licensed provider, named: the site should publish the supervising physician or medical director’s name and state license number, verifiable at the state medical board. (2) Licensed pharmacy partner, named: brand-only providers use manufacturer-partnered pharmacies (NovoCare, LillyDirect); compounded telehealth should name the 503A/503B pharmacy fulfilling prescriptions, searchable at NABP’s accredited list at nabp.pharmacy. (3) Independent certification, displayed: LegitScript displays its seal on certified merchants, verifiable at legitscript.com’s public directory. NABP-accredited pharmacies operate on .pharmacy domains. If a site has none of these, treat it as a sales channel, not a medical service. See the verified directory →